


Charles River inks scientific collaboration with Takeda

16 January 2020 | News | By Sonali Wankhade

The integrated drug discovery collaboration will focus on Takeda's four core therapeutic areas



US based company Charles River has announced a multi-year drug discovery collaboration with Japanese firm Takeda Pharmaceutical Company Limited. Together, Charles River and Takeda will launch multiple integrated programs across Takeda's four core therapeutic areas—oncology, gastroenterology, neuroscience, and rare disease—with the ultimate goal of delivering preclinical candidates that Takeda can advance into clinical development.

Collaboration in Drug Discovery

The alliance combines Charles River's extensive integrated drug discovery expertise and deep scientific bench with Takeda's investments in human data and translation to deliver transformative medicines for patients aligned with Takeda's therapeutic strategies in oncology, gastrointestinal disease, neuroscience and rare disease. Charles River will leverage its end-to-end drug discovery and safety assessment platform to explore potential therapeutic approaches and progress these programs towards candidate status. Takeda will then have the option to advance the preclinical candidates through their clinical development pipeline.

Under the terms of the agreement, Takeda will pay Charles River a one-time, upfront fee to establish the collaboration. Charles River will be eligible to receive development payments with a potential value of over \$50 million per program in preclinical and clinical milestones for candidates that progress to registration. The agreement also includes additional potential commercial milestones of up to \$120 million plus royalties on launched products.

Integrated Drug Discovery Approach

By leveraging an integrated drug discovery approach, Charles River provides Takeda with an effective, cohesive, external one-team solution for driving programs forward. Charles River's drug discovery and development teams have experience across a wide range of therapeutic areas, allowing them to drive these programs forward.

